Organigram Reports Q3 FY2025 Financial Results

TORONTO – Organigram Global Inc. announced record financial results for its third quarter of fiscal 2025, ending June 30, 2025. The company achieved significant growth in revenue and adjusted EBITDA, driven by strategic acquisitions and international expansion, while maintaining a strong balance sheet.

Organigram’s Q3 2025 financials reflect robust growth. Gross revenue reached $110.2 million, a 73% year-over-year (YOY) increase from $63.6 million in Q3 2024, while net revenue rose 72% to $70.8 million from $41.1 million. The growth was primarily fueled by the acquisition of Motif Labs Ltd. and a 208% surge in international sales, which hit $7.4 million, up from $2.4 million in the prior year. Adjusted EBITDA climbed 64% to $5.7 million, compared to $3.5 million in Q3 2024, reflecting improved operational efficiencies and higher recreational Cannabis sales.

Free cash flow turned positive at $5.0 million, a significant improvement from a $4.8 million deficit in Q3 2024, driven by better working capital management. However, the company reported a net loss of $6.3 million, compared to a net income of $2.8 million in the prior year, largely due to non-cash fair value adjustments related to financial instruments held by British American Tobacco. Adjusted gross margin was $24.2 million, or 34% of net revenue, slightly down from 36% in Q3 2024, though management anticipates margin improvements as synergies from the Motif acquisition materialize.

Organigram’s cash position stood at $85.9 million, including $35.9 million in unrestricted cash, with negligible debt, positioning the company to pursue further growth opportunities. The company’s market leadership in Canada remains strong, holding the top spot in vapes, pre-rolls, milled flower, and concentrates, and ranking third in edibles and dried flower, per data from Hifyre, Weedcrawler, and provincial boards.

Organigram’s growth strategy includes both domestic consolidation and international outreach. The acquisition of Motif Labs has delivered $4.2 million in synergies to date, with projections of $15 million annually within two years. The company also entered the U.S. market through its acquisition of Collective Project, launching a direct-to-consumer hemp-derived THC beverage platform across 25 states post-quarter. In Canada, Organigram expanded beverage distribution in Alberta, Saskatchewan, and Manitoba, and introduced new products like SHRED Max10 Party Pack gummies and Trailblazer Blunts.

Internationally, Organigram is pursuing EU-GMP certification for its Moncton facility to bolster export capabilities. The company’s focus on high-potency products was evident in its record Moncton harvest of 24,210 kilograms, averaging over 29% THC potency, supported by seed-based cultivation and capacity enhancements.

Third-party sources, including Nasdaq and Benzinga, corroborate Organigram’s strong Q3 performance, noting its 25% YOY net revenue growth in Q3 2024 and a positive shift in adjusted EBITDA. However, MarketBeat reported that Organigram’s Q1 2025 earnings missed EPS estimates, suggesting potential volatility in earnings consistency. Yahoo Finance highlighted the company’s U.S. expansion and rebranding to Organigram Global Inc. in March 2025, reflecting its ambition to become a global Cannabis leader.